Overview

Trial of Afatinib in Pediatric Tumours

Status:
Completed

Trial end date:
2020-08-05

Target enrollment:

Participant gender:

Summary

Open-label, dose escalation, monotherapy, basket trial with biomarker specific MTD expansion cohort/Phase II part. The trial will consist of 2 parts: 1. Dose finding part to determine the MTD 2. Biomarker specific MTD expansion cohort/Phase II part to assess clinical anti-tumour activity in included tumour types

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Afatinib